EpiVax Therapeutics, Inc. — Form D/A
EpiVax Therapeutics, Inc. of PROVIDENCE, RI, a company, filed a Form D amendment with the SEC on 2018-12-14. The offering totals $2.0M, of which $1.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-12-14
- Form: D/A
- Accession: 0001724741-18-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $1.4M
- Remaining: $595K
- Minimum investment: $25K
- Investors: 14
- Date of first sale: 2017-11-30
- Revenue range: Decline to Disclose
- SEC file number: 021-300416
Issuer
- Name: EpiVax Therapeutics, Inc.
- CIK: 0001724741
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 188 Valley Street, PROVIDENCE, RI, 02909
- Phone: (401) 272-2123
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Richard Lipkin | Director | Cambridge, MA |
| William Martin | Director | Memphis, TN |
| William Martin | Executive Officer | Memphis, TN |
| Daniel Adams | Director | Lehi, UT |
| Clifford Grimm | Executive Officer | Providence, RI |
| Anne De Groot | Director | Providence, RI |
| Anne De Groot | Executive Officer | Providence, RI |
| Gad Berdugo | Director | New York, NY |
| Gad Berdugo | Executive Officer | New York, NY |
Other filings by this issuer (4)
More